-+ 0.00%
-+ 0.00%
-+ 0.00%

Century Therapeutics To Highlight CNTY-813, iPSC-Derived Islet Cell Replacement Therapy Program Engineered With Allo-Evasion 5.0 For Patients With Type 1 Diabetes At ADA 86th Scientific Sessions

Benzinga·04/30/2026 20:27:22
Listen to the news

Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced the company will deliver an oral presentation at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The presentation will highlight CNTY-813, Century's iPSC-derived islet cell replacement therapy program engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes.